AMD 3465

• Description:

  AMD 3465 (GENZ-644494) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.

• Product Name Alternative:

  GENZ-644494

• UNSPSC:

  12352005

• Target:

  CXCR; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; GPCR/G Protein; Immunology/Inflammation

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Infection; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/amd-3465.html

• Purity:

  99.59

• Solubility:

  H2O : ≥ 100 mg/mL

• Smiles:

  C1(CNCC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)=NC=CC=C1

• Molecular Formula:

  C24H38N6

• Molecular Weight:

  410.60

• References & Citations:

  [1]Hatse S, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol. 2005 Sep 1;70 (5) :752-61.|[2]Yang L, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007 Jan 15;67 (2) :651-8.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CXCR4; HIV-1; HIV-2

• Citation 01:

  Br J Haematol. 2023 May;201 (3) :459-469.|Biomed Pharmacother. 2021 Jun:138:111476.|Immunity. 2025 Aug 12:S1074-7613 (25) 00314-0.|J Labelled Comp Radiopharm. 2018 May 15;61 (5) :438-446. |Patent. US20180263995A1.

• CAS Number:

  [185991-24-6]